Camrelizumab Plus Chemoradiotherapy for Patients With Locoregional Cancer of Nasal Cavity and Paranasal Sinuses

Sponsor
Sun Yat-sen University
Study ID
NCT05114707
Phase
PHASE2
Status
Unknown

Conditions

  • Camrelizumab
  • Concurrent Chemotherapy
  • Induction Chemotherapy
  • Intensity Modulated Radiotherapy
  • Nasal Cavity Cancer
  • Paranasal Sinus Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • camrelizumab — DRUG
    Camrelizumab was administrated with 200mg each time, every three weeks for a total of 11 cycles since the first day of induction chemotherapy.

Study Details

Patients with locoregional cancer of nasal cavity and paranasal sinuses are candidate for this study. All the eligible patients receive three cycles of induction chemotherapy (docetaxel 60mg/m2+cisplatin 60mg/m2+5-FU2.5g/m2,civ48h, q3w) followed by concurrent two cycles of cisplatin (80mg/m2,q3w) with curative intensity modulated radiotherapy. Besides, camrelizumab (200mg) is administrated every three weeks for a total of 11 cycles since the first day of induction chemotherapy. We aim to evaluate the three years failure free survival of these patients by the combination of camrelizumab with curative radiotherapy and chemotherapy.

Key Dates

Start date
Apr 16, 2021
Status verified
Nov 2021
Primary completion
Apr 16, 2024
Completion
Apr 16, 2024

Study Design

Enrollment
57 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: camrelizumab group

Primary Outcome Measure

3-year failure free survival [ Time Frame: 3-year ]

Central Contacts

Related Studies